11mins - Expert presentations By Ireti Adejumo
Practical Steps to Better Asthma Control
Dr Ireti Adejumo, expert in respiratory medicine at the University of Nottingham, presents practical steps and tips on how to effectively assess asthma control. Here Dr Adejumo discusses, the symptoms, pathophysiology and future risks of asthma, the definition of asthma control, tools to assess symptom control in asthma patients, how to assess future risk from uncontrolled asthma, what adherence and poor adherence mean for asthma patients, she ends with a practical patient example of how assessing symptom control helps in identifying the need for behaviour change in patients ultimately improving asthma management.
12mins - Expert presentations By Kevin Gruffydd-Jones
Asthma Management: Where Are We Now?
An expert presentation on how to achieve asthma control and management
11mins - Expert presentations By John D Blakey
Asthma: comorbidities and special populations
An expert presentation on Asthma, comorbidities and special populations
50mins - Expert presentations By Centers for Disease Control and Prevention
Zika Virus—What Clinicians Need to Know
Experts from the CDC present a comprehensive overview: Zika Virus-What Clinicians Need to Know, and provide responses to selected questions
16mins - Expert presentations By Univ.-Prof. Dr. med. J. Christian Virchow
Asthma therapy - tailor-made or off-the-shelf?
This presentation deals with the phenotypes and possible endotypes of asthma. The differentiation between allergic asthma and intrinsic asthma (non-allergic asthma) will be discussed. Furthermore, the problems of neutrophilic asthma will be looked at.
16mins - Expert presentations By Ahmed Elsharkawy
Management of HCV in CKD patients
In this expert presentation consultant hepatologist Dr Ahmed Elsharkawy discusses the current recommendations for patients with kidney disease and HCV. Using a case study, he explains what HCV monitoring is required in patients on renal replacement therapy and on dialysis. The HCV treatments to be offered and their evidence of efficacy is also described. Dr Elsharkawy concludes with practical take-home messages to summarize his presentation.
13mins - Expert presentations By Daniel Forton
Real-world effectiveness and safety data in HCV therapy
Dr Daniel Forton, consultant hepatologist at St George’s University Hospitals NHS Foundation Trust, London, reviews the treatment of hepatitis C, especially Direct Acting Antiviral regimes and the importance of real-world data to inform optimal selection of treatments for specific patient groups. He concludes that real-world data suggest there is still a need to tailor treatment duration with the addition of ribavirin in certain situations with certain regimes to optimise efficacy.
10mins - Expert presentations By Graham R Foster
HCV treatment in migrants, prisoners, MSMs
Professor Graham Foster, Professor of Hepatology at Queen Mary University of London, reviews the prevalance of hepatitis C among different communities as well as common treatment barriers and practial solutions. He concludes that modern-day medicine enables a variety of populations to clear viral liver disease, but highlights the challenges of engaging populations such as immigrants, MSMs and prisoners in to hepatitis C therapy.
13mins - Expert presentations By Graham R Foster
HCV treatment in children, adolescents, women and elderly
Professor Graham Foster, Professor of Hepatology at Queen Mary University of London, reviews the safety and efficacy of antivirals for the treatment of HCV infection in children, adolescents, women and elderly patients. He concludes that therapy is likely to be efficacious and well-tolerated with currently available agents, but highlights the importance of a personalised approach to care in all cases.
17mins - Expert presentations By David Back
Managing and monitoring of drug interactions
Professor David Back discusses challenges faced by HCPs when treating patients with hepatitis C infection with co-morbidities and co-medications. He presents a case study to illustrate the online tool developed by the University of Liverpool for the assessment of potential drug-drug interactions. Professor Back concludes that it is essential to review all co-medications (prescribed, OTC, herbals and internet) when starting or stopping treatment in people with HIV and HCV infection.
14mins - Expert presentations By John F Dillon
HCV in People Who Inject Drugs: diagnosis and cure
Professor John Dillon discusses the prevalence of hepatitis C infection in people who inject drugs (PWID) and proposes novel testing methods including use of dried blood spots and point of care testing to improve access to these high risk populations by healthcare professionals. He describes implementation of a programme in Scotland where these novel approaches increased uptake of testing and diagnosis of hepatitis C infection in PWID.
8mins - Expert presentations By Margaret O’Sullivan
Treating HCV in people who inject drugs: engaging the disengaged
Magaret O’Sullivan, Clinical Nurse SpecialistCommunity Care discusses how to engage and manage HCV infection in people who inject drugs (PWID). Only 5% of PWID attend hepatology clinics after their HCV diagnosis, To reduce global HCV deaths, the PWID population needs to be addressed, Community HCV services are an effective way to reach this vulnerable group, Learn about simple things that make the difference topeople wiht HCV infection who inject drugs.
14mins - Expert presentations By Ravi Kalhan, MD, MS
Exploring Asthma-COPD Overlap Syndrome
Join Dr. Ravi Kalhan of the Northwestern University Feinberg School of Medicine for an interesting discussion on asthma-COPD overlap syndrome.
10mins - Expert presentations By Gary Schwartz, MD
Hypertension: Diagnostic Evaluation
Join Dr. Gary Schwartz, Professor of Medicine and Director of the ASH Hypertension Specialists Program, for a brief overview on diagnosing and evaluating hypertension.
7mins - Expert presentations By Pauline M. Camacho, MD, FACE
Assessment of Fracture Risk
Pauline M. Camacho, MD, FACE, director of the Loyola University Osteoporosis and Metabolic Bone Disease Center, discusses the efficacy and limitations of fracture risk prediction tools.
13mins - Expert presentations By Malcolm Finlay
Modern Recognition and Treatment of Atrial Fibrillation
An expert presentation on the modern recognition and treatment of atrial fibrillation
11mins - Expert presentations By Beata Godlewska
Improving Diagnosis and Care for People with Depressive Disorder
Expert presentation on improving diagnosis and care for people with depressive disorder
9mins - Expert presentations By Kamlesh Khunti
Clinical Inertia in Management of People with Type 2 Diabetes
Expert Presentation on the management of type 2 diabetes and the benefits of early intensive therapy
12mins - Expert presentations By Lars Bastholt
Treatment of Metastatic Melanoma in 2019
As a leading expert in the field of metastatic melanoma, Lars Bastholt runs through the recent developments that have transformed treatment of this disease and vastly improved average prognosis. He covers the major trials of drugs targeting the activated MAPK pathway and those blocking CTLA4 and PD1. There is information on which toxicities to look out for with particular regimens, as well as useful guidance on selecting the most appropriate treatment according to patient factors such as disease aggressiveness and molecular biomarkers. Finally, Professor Bastholt looks to trials in progress and how treatment may change in the near future.
17mins - Expert presentations By Mike Youle
Maintaining and optimising long term ARV therapy
In this expert presentation, Professor Mike Youle, Royal Free Hospital, London discusses how antiretroviral therapy (ART) for people with HIV has changed over the years. He considers the issues that he takes into account to ensure the long term health of patients.